TOPIC 343: NEUROPSYCHOLOGICAL ASSESSMENT SYSTEM FOR CANCER PATIENTS

认知能力下降是许多癌症幸存者的主要生活质量问题。各种可用的治疗方法对个体的影响不同，不幸的是，研究对特定治疗如何影响神经认知功能提供了很少的指导。为了帮助研究人员填补这一信息空白，并最终为医生和患者提供指导，需要一个专门为癌症患者和幸存者重复评估而设计的神经心理评估系统。Creare将开发癌症患者神经心理评估系统（NASCP）：一种特定于癌症患者和幸存者的移动的、自我管理的、可重复的神经心理学评估系统，包括移动的应用程序，一个安全的符合HIPAA标准的服务器，以及一个供研究人员和临床医生使用的门户网站。将在人体研究中评估NASCP的组分。

Cognitive decline is a major quality-of-life concern for many cancer survivors. Thevarious available treatments affect individuals differently, and research has unfortunately provided little guidance on how specific treatments impact neurocognitive function. To help researchers fill this information gap and ultimately provide guidance to doctors and patients, a neuropsychological assessment system that is designed specifically for repeated assessment of cancer patients and survivors is needed.Creare will develop the Neuropsychological Assessment System for Cancer Patients(NASCP): a mobile, self-administered, repeatable neuropsychological assessment system specific to cancer patients and survivors comprising of a mobile app, a secure HIPAA-compliant server, and a web portal for researchers and clinicians. The components of the NASCP will be assessed in a human study.